What Is Pituitary Tumors?
Pituitary tumors are mostly benign growths in the pea-sized gland at your brain's base. They affect 10-25% of people on imaging, though only about 1 in 1,000 develop symptoms1. Men over 50 see the highest rates of clinical problems.
These tumors disrupt testosterone production through direct pressure. The mass compresses normal pituitary tissue, blocking the signals that tell your testes to make testosterone. That creates secondary hypogonadism — low testosterone caused by a pituitary problem, not a testicular one. Nonfunctioning adenomas, which don't secrete hormones themselves, are the most common type that tanks testosterone levels2.
Key Takeaways
Pituitary tumors compress normal pituitary tissue, shutting down testosterone production through disrupted LH and FSH signaling. Most are benign and treatable with surgery or medication. TRT effectively restores testosterone levels after tumor control.
- Reversibility: Many recover natural production after tumor removal
- Monitoring: Lifelong MRI surveillance required for recurrence detection
Signs and Symptoms
Pituitary tumor symptoms split into two categories: mass effects from the tumor pressing on nearby structures, and hormone deficiency symptoms from disrupted testosterone production.
Headaches & Vision Loss
Persistent headaches and peripheral vision loss occur when the tumor compresses the optic chiasm above the pituitary gland.
Fatigue & Low Energy
Persistent exhaustion and decreased physical stamina develop as testosterone levels drop below normal ranges.
Low Libido & ED
Sexual desire plummets and erectile function weakens when testosterone production falls significantly.
Mood Changes & Brain Fog
Depression, irritability, and difficulty concentrating emerge as both tumor effects and testosterone deficiency symptoms.
Severity varies by tumor size. Microadenomas under 10mm may produce subtle symptoms or none at all. Macroadenomas over 10mm cause more obvious mass effects3.
Vision problems warrant urgent evaluation. The classic pattern is bitemporal hemianopsia, where you lose peripheral vision on both sides. If you develop new headaches with vision changes, see a doctor immediately4.
Bitemporal Hemianopsia is a characteristic vision loss pattern where peripheral vision is lost on both sides of the visual field, occurring when a pituitary tumor compresses the optic chiasm.
Macroadenoma is a pituitary adenoma larger than 10mm that typically causes noticeable mass effects and compression symptoms on surrounding structures.
Why It Happens
HPG Axis Compression
Tumor mass physically compresses the pituitary stalk, disrupting GnRH signals from the hypothalamus. Without proper GnRH pulsing, the pituitary releases insufficient LH and FSH. Your testes never receive the signal to produce testosterone2.
Prolactin Interference
Prolactinomas secrete excessive prolactin, which directly suppresses GnRH pulsatility through dopaminergic pathways. Prolactin levels above 20 ng/mL indicate a likely prolactin-secreting tumor. This hormonal interference shuts down testosterone production independent of physical compression5.
Secondary Hypogonadism Pattern
Pituitary tumors cause low testosterone with simultaneously low or inappropriately normal LH and FSH. This distinguishes it from primary testicular failure, where LH and FSH rise trying to compensate. Some cases also show elevated SHBG, which further reduces bioavailable free testosterone.
Age over 40 increases risk for clinically significant adenomas. Macroadenomas carry higher risk for hormonal dysfunction than smaller tumors. Male sex correlates with later presentation, as men often ignore subtle symptoms until mass effects become obvious6.
Diagnosis and Testing
Brain MRI is the gold standard for detecting pituitary tumors. The scan distinguishes microadenomas under 10mm from macroadenomas over 10mm3.
Hormone testing confirms secondary hypogonadism. Draw blood between 7-11 AM on two separate mornings for accuracy.
| Test | Reference Range | Deficiency Threshold |
|---|---|---|
| Total Testosterone | 300-1000 ng/dL | <300 ng/dL |
| Luteinizing Hormone (LH) | 1.5-9.0 IU/L | <1.5 IU/L |
| Follicle-Stimulating Hormone (FSH) | 2.0-10.0 IU/L | <2.0 IU/L |
| Prolactin | <15 ng/mL | >20 ng/mL suggests prolactinoma |
| IGF-1 | Age-dependent | Low indicates GH deficiency |
| TSH & Free T4 | 0.4-4.0 mIU/L, 0.8-1.8 ng/dL | Low values suggest hypothyroidism |
| Morning Cortisol | >10 mcg/dL | <5 mcg/dL indicates adrenal insufficiency |
The pattern of low testosterone with low LH and FSH confirms secondary hypogonadism7. This distinguishes pituitary causes from primary testicular failure, where LH and FSH would be elevated.
Clinical criteria include persistent headaches, visual field defects, and evidence of hormone deficiencies. The formal ICD-10 code is D35.2 for benign pituitary neoplasm.
Your doctor may order visual field testing. The classic finding is bitemporal hemianopsia, peripheral vision loss caused by optic chiasm compression8.
Differential diagnoses include primary hypogonadism, obstructive sleep apnea, obesity-related hypogonadism, hemochromatosis, and other sellar masses like craniopharyngiomas. MRI distinguishes pituitary adenomas from these other conditions.
Treatment and Management
Treatment strategy depends on tumor type, size, and symptoms. Address the tumor first, then manage residual hormone deficiencies.
Transsphenoidal Surgery
First-line for symptomatic nonfunctioning macroadenomas. Surgeons access the tumor through your nose. Remission rates hit 70-90% for microprolactinomas3.
Medical Therapy
Cabergoline 0.5-2 mg weekly is first-line for prolactinomas, reducing prolactin and restoring testosterone in 80-90% of cases. Somatostatin analogs treat growth hormone-secreting tumors.
Radiation Therapy
Reserved for tumors that don't respond to surgery or medication. Used when residual tumor mass persists or recurrence occurs.
Testosterone Replacement
Testosterone cypionate 100-200 mg IM weekly or daily gels restore levels after tumor control. TRT improves libido, energy, and muscle mass. Monitor hematocrit and estradiol levels.
Multi-Axis Replacement
Many patients need hydrocortisone for adrenal insufficiency or levothyroxine for hypothyroidism. All pituitary hormone axes require evaluation and replacement as needed.
TRT is second-line after addressing tumor burden. Starting testosterone before tumor control may mask symptoms and delay necessary intervention. In prolactinomas, treating with cabergoline often restores natural testosterone production, making TRT unnecessary.
Post-surgery recovery takes 4-8 weeks for most physical restrictions. TRT response shows improvement in 4-12 weeks, with peak benefits at 6 months. One study showed hematocrit rising from 38% to 45% in men receiving TRT after tumor treatment6.
Monitor testosterone, LH, FSH, and prolactin every 3-6 months initially. Repeat MRI at 6-12 months post-surgery to confirm tumor removal or response to medical therapy2. Long-term follow-up continues indefinitely, as recurrence can occur years later.